KAI1基因抑制人胰腺癌细胞转移的体内实验  

KAI1 gene inhibits in vivo metastasis of human pancreatic cancer.

作　　者：徐建华[1] 任丽楠[1] 邵丽春 郭晓钟[1] 刘民培[1] 

机构地区：[1]沈阳军区总医院消化科,110016 [2]解放军第463医院消化科

出　　处：《胰腺病学》2006年第1期8-11,共4页Chinese JOurnal of Pancreatology

基　　金：国家自然科学基金资助项目(39970344);全军"十五"杰出人才基金项目(01J001号)

摘　　要：目的研究体内直接注射KAI1基因抗胰腺癌转移作用。方法MiaPaCa胰腺癌细胞裸鼠皮下接种后,随机分为2个大组(接种后第10天和第21天治疗组),每组再分别瘤内注射pCMV-KAI1重组质粒100μg,pCMV-KAI1-脂质体(50μg∶50μg)和生理盐水,每7d注射1次,共注射3次。于第50天观察KAI1对胰腺癌生长转移影响。结果接种后10d进行基因注射组中,KAI1治疗组和脂质复合物治疗组肿瘤体积、瘤重、肺重、肝重和肺表面转移结节数均小于对照组(P<0.05),体积抑瘤率分别为63.79%和73.51%,瘤重抑瘤率分别为77.12%和83.26%,肺重分别为(0.33±0.09)g和(0.30±0.09)g,肝重分别为(1.01±0.27)g和(0.99±0.21)g,对照组肺肝重分别为(0.45±0.09)g和(1.62±0.39)g,对照组肺表面转移结节数平均为(2.33±1.63)个,治疗组结节数仅为(0.5±0.83)个。pCMV-KAI1治疗组与脂质复合物治疗组相比差异无显著性(P>0.05);接种后21d进行基因注射组中,治疗组肿瘤体积、瘤重、肺重、肺转移灶和肝重与对照组相比差异无显著性(P>0.05)。结论KAI1基因瘤内注射具有抑制MiaPaCa胰腺癌生长及转移作用,KAI1基因对已成瘤的胰腺癌生长的抑制作用与瘤内给药时间密切相关。Objective To evaluate the role of KAI1 gene injection in inhibiting metastasis of pancreatic cancer in vivo. Methods Heterotopic human pancreatic adenocarcinoma was successfully established in the groin of BALB/C nude mice by subcutaneous injection of MiaPaCa Ⅱ pancreatic cancer cells. The tumor-bearing mice were randomly divided into two groups： day-10 group, where treatment was started from the 10^th day of cancer cell inoculation, and day-21 group, where treatment was started from the 10^th day of cancer cell inoculation. 100μg recombinantplasmid pCMV-KAI1, 100 tzg pCMV-KAI1-LipofectAMINE （1 ： 1 ）, or 100 tzl saline was directly injected into pancreatic adenocarcinoma at a 7-day interval for three times. At day 50, the tumor growth and metastasis were measured. Results In the KAI1 group and KAI1-LipofectAMINE group of day-10 group, the tumor volume inhibitory rate of treatment group and control group was 63.79% vs 73.51%, the tumor weight inhibitory rate was 77.12% vs 83.26%, the weight of lung was （0.33 ± 0.09）g vs （0.30 ± 0.09）g, the weight of liver was （1.01 ± 0.27）g vs （0.99 ± 0.21）g, and the lung metastatic nodule number was 0.5 ± 0.83 vs 2.33 ± 1.63, respectively. These data were less than those of control group（P 〈 0.05）. There was no significant difference between KAI1 group and KAI1-LipofectAMINE group （P〉 0. 05）. In 21-day group, there was no significant difference in tumor volume, tumor weight, weight of lung, weight of liver and the lung metastatic nodule number between gene therapy group and saline control group （P 〉 0. 05）. Conclusions KAI1 gene directly injected into pancreatic adenocarcinoma plays an important role in inhibiting the growth and metastasis of MiaPaCa Ⅱ pancreatic cancer. The suppressive role of KAI1 gene was closely correlated with the time phase of injecting gene into tumor.

关 键 词：胰腺肿瘤 基因注射 KAI1基因 

分 类 号：R735.9[医药卫生—肿瘤] R735.7[医药卫生—临床医学]